Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

New Stock Coverage: Frozen Smiles All Around for Botox Maker Allergan


Wall Street ratings agencies set the tone for today's stock market.

MINYANVILLE ORIGINAL Shares snapped a six-week winning steak after the S&P 500 Index (^GSPC) had earlier hit a four-year high. The damage was nonetheless minor and equities actually concluded with their best session since the start of August. This as a letter sent on Wednesday by Ben Bernanke to Representative Darrell Issa came to light on Friday, the two-day intra-DC turnaround being about right for the Postal Service. Bernanke's missive was, in turn, a response to a 10-page, 22-question inquiry Issa sent the Fed head himself on August 1. If nothing else, the two power players deserve immense credit for single-handedly trying to revive the moribund fortunes of both the mail and Eastman Kodak's (EKDKQ) printing business. Yet with Congress currently on an immensely well paid five-week vacation, one worries that the contents will look "a bit stale," as it were, when Issa eventually reads it. No top-tier economic data due today, but Donaldson (DCI), Pointer Telocation (PNTR), PVH Corp. (PVH), SeaDrill (SDRL), and Tiffany (TIF) are all expected to announce quarterly earnings.

Allergan (AGN): The Botox maker is begun with an Outperform at William Blair, which assigns it a price objective of $100.

Annie's Inc. (BNNY): Credit Suisse covers the company at Outperform and sets a $48 target price.

Bonanza Creek Energy (BCEI): Shares are begun with a Sector Perform at RBC Capital, whose target is $25.

Eloqua (ELOQ): The software stock is initiated with Buys at both Needham ($18 objective) and Deutsche Bank, while JPMorgan (Overweight) and JMP Securities (Outperform) are equally upbeat.

FactSet Research Systems (FDS): FDS is a fresh Market Perform at William Blair.

Globus Medical (GMED): Blair begins Outperform rated research.

Jazz Pharmaceuticals (JAZZ): The stock is initiated with a Buy at brokerage boutique WallachBeth, whose price target is $63. They say sales may reach $1 billion in 2014, propelled by orphan-type drugs including Xyrem, Erwinaze and Prialt.

Mosaic (MOS): The fertilizer firm is a fresh Hold at Topeka.

New York Mortgage Trust (NYMT): Ladenburg launches Buy rated coverage, and establishes a $7.50 target.

Sarepta Therapeutics (SRPT): Shares are begun with a Buy at ThinkEquity, whose objective is $15.

(See also: Stock Upgrades: Madison Square Garden in Full Bloom and Stock Downgrades: Autodesk Takes a Back Seat.)
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos